IMAGO BIOSCIENCES INC (IMGO)

US45250K1079 - Common Stock

36.01  +0.01 (+0.03%)

After market: 36.01 0 (0%)

Fundamental Rating

3

Taking everything into account, IMGO scores 3 out of 10 in our fundamental rating. IMGO was compared to 587 industry peers in the Biotechnology industry. IMGO has a great financial health rating, but its profitability evaluates not so good. IMGO is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMGO had negative earnings in the past year.
In the past year IMGO has reported a negative cash flow from operations.

1.2 Ratios

The profitability ratios for IMGO are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMGO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

IMGO has more shares outstanding than it did 1 year ago.
IMGO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

IMGO has an Altman-Z score of 51.58. This indicates that IMGO is financially healthy and has little risk of bankruptcy at the moment.
IMGO's Altman-Z score of 51.58 is amongst the best of the industry. IMGO outperforms 98.60% of its industry peers.
There is no outstanding debt for IMGO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 51.58
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 13.16 indicates that IMGO has no problem at all paying its short term obligations.
IMGO has a Current ratio of 13.16. This is amongst the best in the industry. IMGO outperforms 80.72% of its industry peers.
A Quick Ratio of 13.16 indicates that IMGO has no problem at all paying its short term obligations.
IMGO has a better Quick ratio (13.16) than 80.72% of its industry peers.
Industry RankSector Rank
Current Ratio 13.16
Quick Ratio 13.16

More info and screens

1

3. Growth

3.1 Past

IMGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.94%.
EPS 1Y (TTM)-69.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-13.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

IMGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.80% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.56%
EPS Next 2Y14.27%
EPS Next 3Y6.87%
EPS Next 5Y8.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.27%
EPS Next 3Y6.87%

More info and screens

0

5. Dividend

5.1 Amount

IMGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMAGO BIOSCIENCES INC

NASDAQ:IMGO (1/10/2023, 7:15:28 PM)

After market: 36.01 0 (0%)

36.01

+0.01 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.22B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 13.16
Quick Ratio 13.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-69.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y46.56%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y